fda warning compounded semaglutide october 2025 Compound versions of GLP-1 drugs for weight loss halted by FDA Issues Warnings Against Illegal

However, the UPenn study published in Nature Health found that women in a large real-world dataset reported menstrual changes with enough frequency to suggest the topic warrants more systematic research

[DOI] [PubMed] [Google Scholar] 136.Friedman JM, Halaas JL

The latest GLP-1 coverage expansion and AI initiatives support the existing narrative but do not materially change these near term drivers

Because AOD 9604 does not bind the growth hormone receptor, it does not trigger the IGF-1 cascade

By the time obvious signs appear, the deficiency has usually been present for some time

Any future settlements will depend on how the cases develop